Compare · GHRS vs NVO
GHRS vs NVO
Side-by-side comparison of GH Research PLC (GHRS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GHRS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.64B, about 112.4x GHRS ($1.71B).
- Over the past year, GHRS is up 100.9% and NVO is down 40.8% - GHRS leads by 141.7 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 9 for GHRS).
- NVO has more recent analyst coverage (25 ratings vs 13 for GHRS).
- Company
- GH Research PLC
- Novo Nordisk A/S
- Price
- $24.48-1.73%
- $42.01-2.10%
- Market cap
- $1.71B
- $191.64B
- 1M return
- +12.97%
- -5.38%
- 1Y return
- +100.90%
- -40.76%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 9
- 11
- Recent ratings
- 13
- 25
GH Research PLC
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GHRS
- SEC Form 6-K filed by GH Research PLC
- SEC Form EFFECT filed by GH Research PLC
- SEC Form 6-K filed by GH Research PLC
- SEC Form F-3 filed by GH Research PLC
- SEC Form 424B5 filed by GH Research PLC
- SEC Form 6-K filed by GH Research PLC
- GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
- SEC Form 6-K filed by GH Research PLC
- SEC Form 6-K filed by GH Research PLC
- SEC Form 6-K filed by GH Research PLC
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates